Annovis Bio, Inc. (ANVS) Stock Forecast
Data as of May 10, 2026Healthcare · Current price $2.29 (+1.77%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
ANVS vs Sector & Market
| Metric | ANVS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 1 | 8 | 19 |
| Target Upside | +1021.0% | +1709.7% | +16.4% |
| P/E Ratio | -1.61 | 3.30 | 27.60 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $11M | $11M | $11M | 2 |
| 2027-12-31 | $17M | $17M | $17M | 2 |
| 2028-12-31 | $51M | $51M | $51M | 2 |
| 2029-12-31 | $209M | $209M | $209M | 1 |
| 2030-12-31 | $385M | $385M | $385M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-1.25 | $-1.25 | $-1.25 | 1 |
| 2027-12-31 | $-1.18 | $-1.18 | $-1.18 | 1 |
| 2028-12-31 | $-2.01 | $-1.61 | $-1.21 | 2 |
| 2029-12-31 | $-0.40 | $-0.40 | $-0.40 | 1 |
| 2030-12-31 | $1.70 | $1.70 | $1.70 | 1 |
Frequently Asked Questions
What is the analyst consensus for ANVS?
The consensus among 1 analysts covering Annovis Bio, Inc. (ANVS) is Buy with an average price target of $25.67.
What is the highest price target for ANVS?
The highest analyst price target for ANVS is $30.00.
What is the lowest price target for ANVS?
The lowest analyst price target for ANVS is $21.00.
How many analysts cover ANVS?
1 analysts have issued ratings for Annovis Bio, Inc. in the past 12 months.
Is ANVS a buy or sell right now?
Based on 1 analyst ratings, ANVS has a consensus rating of Buy (2.00/5) with a +1021.0% upside to the consensus target of $25.67.
What are the earnings estimates for ANVS?
Analysts estimate ANVS will report EPS of $-1.25 for the period ending 2026-12-31, with revenue estimated at $11M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.